Bayer, Zydus extend pharma JV by 3 years

Mumbai: German chemical and

pharma

major

Bayer

and Ahmedabad-based Cadila Healthcare on Monday extended their pharmaceuticals joint venture by three years from June 2021. The companies first entered into an agreement in January 2011 to set up Bayer

Zydus Pharma

for sales and marketing of pharmaceuticals in the country, the company said.

During the term of the joint venture, the company launched Bayer’s global assets including Xarelto, Eylea and Visanne.

Bayer Zydus

Pharma will continue to operate in core therapies including cardiovascular diseases, diabetes, women’s health, ophthalmology and oncology, with new products in the pipeline. Key products in the company’s pharmaceutical portfolio include Xarelto, Glucobay, Eylea, Yaz, Mirena and Visanne, the company added.

Bayer Zydus Pharma operates across the core business units of general medicine, women’s healthcare and specialty medicine for cardiovascular diseases, anti-diabetic treatments, ophthalmology, oncology and radiology, with new products in the pipeline.